| Market Report -- In Play (IDRA) - MSN Money |
|
|
MSN MoneyIdera Pharma presents final data from Phase 2 clinical trial of IMO-2055 monotherapy in renal cell carcinoma; median overall survival was 23.5 months ...Idera Pharmaceuticals Presents Final Data from Phase 2 Clinical ... Business Wire (press release)Idera Pharmaceuticals presents final data from clinical trial ... Therapeutics Daily (press release) (registration)Idera Pharmaceuticals Presents Interim Data From Phase 1b Clinical ... read more |